Developer docs
API playgroundTry for free, no card

Search company profiles

Coherus Biosciences

Full company profile

uuid0002n64

Namestring
Coherus Biosciences
Legal namestring
Coherus BioSciences, Inc.
Websiteurl
coherus.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Coherus Biosciences (now operating as Coherus Oncology) is a Redwood City, California-based commercial-stage biopharmaceutical company that develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases. Founded in 2010 by Denny Lanfear and listed on NASDAQ under ticker CHRS, the company employs 101-250 people and operates a corporate headquarters at 333 Twin Dolphin Drive in Redwood City with a laboratory and manufacturing facility in Camarillo, California. Coherus underwent a strategic transformation in the 2023-2025 period, divesting its legacy pegfilgrastim biosimilar franchise (UDENYCA, sold to Intas Pharmaceuticals for $558.4 million in August 2025) and pivoting to become a pure-play immuno-oncology innovator.

The company's core product is LOQTORZI (toripalimab-tpzi), a next-generation anti-PD-1 monoclonal antibody that received FDA approval on October 27, 2023 for the treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), making it the only FDA-approved therapy for this indication. Clinical data from the Phase 3 JUPITER-02 trial demonstrated a 38% reduction in risk of death and a 31-month improvement in median overall survival (64.8 vs 33.7 months) versus chemotherapy alone. The company is building a diversified immuno-oncology pipeline around the LOQTORZI backbone with two clinical-stage candidates: tagmokitug (anti-CCR8, designed to selectively deplete tumor-resident regulatory T cells) and casdozokitug (anti-IL-27, first-in-class antibody antagonist with FDA Orphan Drug designation for hepatocellular carcinoma). Pipeline indications span hepatocellular carcinoma, head and neck squamous cell carcinoma, gastric/GEJ/esophageal cancers, colorectal cancer, and metastatic castration-resistant prostate cancer.

Coherus generates revenue through direct US sales of LOQTORZI to oncologists, hospitals, and cancer treatment centers via an enterprise field sales force, supported by medical affairs and market access teams. International commercialization is pursued through licensing partnerships, with Apotex Inc. holding exclusive Canadian rights following Health Canada approval in October 2025. Revenue is supplemented by licensing and royalty streams from such partnerships. FY2025 LOQTORZI net revenue was $40.8 million (more than doubled from $19 million in 2024), with Q1 2026 revenue of $11.8 million representing 61% year-over-year growth. The company maintains clinical collaborations with Johnson & Johnson (tagmokitug combination in mCRPC), Zumutor Biologics (ZM008 combination), and Inovio Pharmaceuticals (DNA-based cancer immunotherapy combinations) to extend the platform without full infrastructure investment. As of Q1 2026, the company held $167.0 million in cash and cash equivalents with debt reduced to $3.7 million following the UDENYCA divestiture.

Short descriptiontext

Coherus Biosciences is a Redwood City-based biopharmaceutical company that develops and commercializes immuno-oncology therapeutics, led by FDA-approved LOQTORZI (toripalimab) for nasopharyngeal carcinoma and a clinical pipeline of anti-CCR8 and anti-IL-27 antibody candidates targeting solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, monoclonal antibody drugs, oncology biologics, PD-1 inhibitors, cancer immunotherapy
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Immuno-Oncology Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1LOQTORZI Product Sales
TypeOne Time License
Description

Revenue from sales of FDA-approved PD-1 inhibitor LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma treatment in the US market. Q1 2026 net revenue of $11.8 million representing 61% increase over Q1 2025. Full year 2025 net revenue of $40.8 million, more than doubled from $19 million in 2024.

stocktitan.net
2Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Revenue from licensing Canadian commercialization rights for LOQTORZI to Apotex Inc., and potential future licensing deals for ex-US development and commercialization rights in emerging markets.

apotex.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LOQTORZI
Description

FDA-approved PD-1 inhibitor (toripalimab-tpzi) for treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma

coherus.com
+2 more records
Core offering1 text field

Coherus Biosciences (also known as Coherus Oncology) develops, manufactures, and commercializes biologic therapeutics for oncology. Its commercial product LOQTORZI (toripalimab-tpzi) is an FDA-approved next-generation anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma. The company is also advancing a clinical pipeline of novel immuno-oncology antibodies including tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27) that target the tumor microenvironment to overcome immune resistance in solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 38% reduction in risk of death (HR 0.62) and 31-month improvement in median OS (64.8 vs 33.7 months) with LOQTORZI plus chemotherapy vs chemotherapy alone in nasopharyngeal carcinoma
+1 more record
Product overview1 text field

Coherus Oncology is a commercial-stage biopharmaceutical company focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies. The company's core product is LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma. Coherus is building a pipeline of novel immuno-oncology candidates including Tagmokitug (anti-CCR8 antibody) and Casdozokitug (anti-IL-27 antibody), targeting the tumor microenvironment to overcome immune resistance in cancer. The company previously commercialized biosimilar products including UDENYCA, which was sold to Intas Pharmaceuticals in 2025.

Product and service3 records
1LOQTORZI (toripalimab-tpzi)
CategoryImmuno-oncology therapeutic / PD-1 inhibitor
Description

LOQTORZI is a next-generation PD-1 monoclonal antibody that blocks PD-L1 and PD-L2 binding to the PD-1 receptor with high potency at a unique site, enabling the immune system to activate and kill tumors. It is the only FDA-approved therapy for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, indicated for use in combination with chemotherapy or as monotherapy. It is sold to oncologists, hospitals, and cancer treatment centers in the United States.

2Tagmokitug (anti-CCR8)
CategoryImmuno-oncology therapeutic / Anti-CCR8 antibody
Description

Tagmokitug is a highly selective anti-CCR8 cytolytic antibody (ADCC-enhanced) designed to selectively deplete tumor resident regulatory T cells (Tregs) that suppress anti-tumor immune response, while sparing T cells and CCR8-negative Tregs in normal tissue. It is being developed for solid tumor indications including metastatic castration-resistant prostate cancer.

3Casdozokitug (anti-IL-27)
CategoryImmuno-oncology therapeutic / Anti-IL-27 antibody
Description

Casdozokitug is a first-in-class anti-IL-27 antibody antagonist designed to inhibit the immunosuppressive activity of IL-27 cytokine, enabling anti-tumor immune activation when combined with other cancer therapies including anti-PD-1 inhibitors. It has received FDA Orphan Drug designation for hepatocellular carcinoma.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Zumutor Biologics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Clinical collaboration to evaluate ZM008 in combination with LOQTORZI (toripalimab-tpzi). Both parties will retain their respective commercial rights. No additional details regarding financial terms disclosed.

bitget.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Clinical supply agreement for a Phase 1b trial evaluating JNJ's pasritamig (T-cell engaging bispecific antibody) in combination with Coherus's tagmokitug in metastatic castration-resistant prostate cancer (mCRPC). Oppenheimer cited this as additional large pharma validation of the CCR8 target.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-23
Description

Licensing agreement granting Apotex exclusive rights to commercialize and sell LOQTORZI in Canada. Apotex received Health Canada approval for LOQTORZI as the first and only Health Canada-approved immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer. This marks Apotex's first novel biologic therapy.

Strategic tierMinorTypeOthersAnnounced on2025-08-01
Description

Intas Pharmaceuticals acquired the Udenyca franchise from Coherus BioSciences for $558.4 million, strengthening both companies' positions in the pegfilgrastim biosimilar segment. The deal closed in August 2025.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership to advance DNA-based cancer immunotherapies combining INO-3113 with LOQTORZI for HPV-associated cancers.

6Surface Oncology Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Coherus acquired Surface Oncology in a stock-for-stock transaction valued at up to $65 million, expected to close in Q3 2023. The acquisition expanded Coherus' immuno-oncology pipeline with SRF388 (now casdozokitug, anti-IL-27) and SRF114 (now tagmokitug, anti-CCR8), targeting the tumor microenvironment.

openpr.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owner of Keytruda (pembrolizumab), the dominant PD-1 inhibitor and Coherus's primary competitor in the broader checkpoint inhibitor space. While not a direct competitor in NPC, Keytruda represents the benchmark that any LOQTORZI label expansion will be measured against. Both companies operate in immuno-oncology with monoclonal antibody platforms.

2Bristol-Myers Squibb
TypeBroad incumbent
Description

Owner of Opdivo (nivolumab), the second-leading PD-1 inhibitor globally. BMS has board representation connected to Coherus through former employees, and Opdivo competes with LOQTORZI in shared indications (head/neck cancer, gastric cancer). BMS represents the established PD-1 incumbent that Coherus must differentiate against.

TypeDirect peer
Description

Commercializes tislelizumab, a Chinese-developed PD-1 antibody with global commercialization. BeiGene is the most direct competitive peer to Coherus — a smaller biopharmaceutical company that has leveraged a Chinese-originated PD-1 antibody to build a US/EU oncology franchise, mirroring Coherus's toripalimab strategy. Both companies target similar hematology/oncology indications with checkpoint inhibitors.

TypeDirect peer
Description

Chinese biopharmaceutical company that developed sintilimab (PD-1) and partners with Eli Lilly for international markets. Innovent is a direct strategic peer to Coherus in bringing a Chinese-originated PD-1 antibody to global markets, with overlapping oncology indications and similar partnership-driven commercial models.

Description

Original developer of toripalimab (LOQTORZI's active ingredient) and Coherus's licensor for US/Canada rights. Junshi is the originator peer — both companies commercialize the same molecule in different geographies, with Coherus holding North American rights. Junshi also commercializes other immuno-oncology assets including anti-PD-L1 (adebrelimab) and anti-BTLA (tifcemalimab), making it a directly comparable Chinese immuno-oncology peer.

TypeBroad incumbent
Description

Established antibody platform company with multiple FDA-approved biologics including Libtayo (cemiplimab, a PD-1 inhibitor). Regeneron is a broad incumbent in monoclonal antibody therapeutics with a deep pipeline in immuno-oncology, oncology bispecifics, and inflammation — directly relevant to Coherus's IO antibody platform approach.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing monoclonal antibodies and antibody-drug conjugates for cancer, including PD-1 inhibitors and Fc-engineered antibodies. MacroGenics is a comparable emerging immuno-oncology peer with similar size and pipeline-stage assets targeting solid tumors with antibody-based mechanisms.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing INDUKINE therapeutics (tumor microenvironment-targeted immunotherapies). Werewolf focuses on overcoming immune resistance through innovative mechanisms — directly comparable to Coherus's CCR8/IL-27 tumor microenvironment approach.

TypeEmerging player
Description

Israel-based clinical-stage immuno-oncology company developing computational-discovered antibody therapeutics targeting novel immune checkpoints, including PVRIG and TIGIT. Compugen's AI-driven antibody discovery and focus on next-generation immune checkpoints parallels Coherus's portfolio approach to overcoming immune resistance.

TypeBroad incumbent
Description

Major biopharmaceutical company with oncology franchise including Trodelvy (ADC) and cell therapy via Kite. Gilead has a history of acquiring smaller oncology companies (Immunomedics, Forty Seven) and Coherus CFO Bryan McMichael previously worked at Gilead. While not a direct PD-1 competitor, Gilead is a relevant strategic acquirer and peer in the oncology therapeutics space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds20 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coherus Biosciences

Immuno-Oncology Biopharmaceuticalscoherus.com

Coherus Biosciences is a Redwood City-based biopharmaceutical company that develops and commercializes immuno-oncology therapeutics, led by FDA-approved LOQTORZI (toripalimab) for nasopharyngeal carcinoma and a clinical pipeline of anti-CCR8 and anti-IL-27 antibody candidates targeting solid tumors.

What Coherus Biosciences does

Coherus Biosciences (now operating as Coherus Oncology) is a Redwood City, California-based commercial-stage biopharmaceutical company that develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases. Founded in 2010 by Denny Lanfear and listed on NASDAQ under ticker CHRS, the company employs 101-250 people and operates a corporate headquarters at 333 Twin Dolphin Drive in Redwood City with a laboratory and manufacturing facility in Camarillo, California. Coherus underwent a strategic transformation in the 2023-2025 period, divesting its legacy pegfilgrastim biosimilar franchise (UDENYCA, sold to Intas Pharmaceuticals for $558.4 million in August 2025) and pivoting to become a pure-play immuno-oncology innovator.

The company's core product is LOQTORZI (toripalimab-tpzi), a next-generation anti-PD-1 monoclonal antibody that received FDA approval on October 27, 2023 for the treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), making it the only FDA-approved therapy for this indication. Clinical data from the Phase 3 JUPITER-02 trial demonstrated a 38% reduction in risk of death and a 31-month improvement in median overall survival (64.8 vs 33.7 months) versus chemotherapy alone. The company is building a diversified immuno-oncology pipeline around the LOQTORZI backbone with two clinical-stage candidates: tagmokitug (anti-CCR8, designed to selectively deplete tumor-resident regulatory T cells) and casdozokitug (anti-IL-27, first-in-class antibody antagonist with FDA Orphan Drug designation for hepatocellular carcinoma). Pipeline indications span hepatocellular carcinoma, head and neck squamous cell carcinoma, gastric/GEJ/esophageal cancers, colorectal cancer, and metastatic castration-resistant prostate cancer.

Coherus generates revenue through direct US sales of LOQTORZI to oncologists, hospitals, and cancer treatment centers via an enterprise field sales force, supported by medical affairs and market access teams. International commercialization is pursued through licensing partnerships, with Apotex Inc. holding exclusive Canadian rights following Health Canada approval in October 2025. Revenue is supplemented by licensing and royalty streams from such partnerships. FY2025 LOQTORZI net revenue was $40.8 million (more than doubled from $19 million in 2024), with Q1 2026 revenue of $11.8 million representing 61% year-over-year growth. The company maintains clinical collaborations with Johnson & Johnson (tagmokitug combination in mCRPC), Zumutor Biologics (ZM008 combination), and Inovio Pharmaceuticals (DNA-based cancer immunotherapy combinations) to extend the platform without full infrastructure investment. As of Q1 2026, the company held $167.0 million in cash and cash equivalents with debt reduced to $3.7 million following the UDENYCA divestiture.

Coherus Biosciences firmographics

Firmographics
Name
Coherus Biosciences
Legal name
Coherus BioSciences, Inc.
Website
https://coherus.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Short description
Coherus Biosciences is a Redwood City-based biopharmaceutical company that develops and commercializes immuno-oncology therapeutics, led by FDA-approved LOQTORZI (toripalimab) for nasopharyngeal carcinoma and a clinical pipeline of anti-CCR8 and anti-IL-27 antibody candidates targeting solid tumors.
Ownership category
akta.pro rank

Coherus Biosciences industry classification

Industry
Product category
Immuno-Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Immuno-oncology therapeutics
  • Monoclonal antibody drugs
  • Oncology biologics
  • PD-1 inhibitors
  • Cancer immunotherapy

Where Coherus Biosciences is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Coherus Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

  1. LOQTORZI Product Sales: Revenue from sales of FDA-approved PD-1 inhibitor LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma treatment in the US market. Q1 2026 net revenue of $11.8 million representing 61% increase over Q1 2025. Full year 2025 net revenue of $40.8 million, more than doubled from $19 million in 2024.
  2. Licensing and Royalty Revenue: Revenue from licensing Canadian commercialization rights for LOQTORZI to Apotex Inc., and potential future licensing deals for ex-US development and commercialization rights in emerging markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Coherus Biosciences product offering

Product offering

Core offering

Coherus Biosciences (also known as Coherus Oncology) develops, manufactures, and commercializes biologic therapeutics for oncology. Its commercial product LOQTORZI (toripalimab-tpzi) is an FDA-approved next-generation anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma. The company is also advancing a clinical pipeline of novel immuno-oncology antibodies including tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27) that target the tumor microenvironment to overcome immune resistance in solid tumors.

Product overview

Coherus Oncology is a commercial-stage biopharmaceutical company focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies. The company's core product is LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma. Coherus is building a pipeline of novel immuno-oncology candidates including Tagmokitug (anti-CCR8 antibody) and Casdozokitug (anti-IL-27 antibody), targeting the tumor microenvironment to overcome immune resistance in cancer. The company previously commercialized biosimilar products including UDENYCA, which was sold to Intas Pharmaceuticals in 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • LOQTORZI: FDA-approved PD-1 inhibitor (toripalimab-tpzi) for treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma
  • Coherus Solutions
  • Toripalimab-tpzi

Products and services

  • LOQTORZI (toripalimab-tpzi) LOQTORZI is a next-generation PD-1 monoclonal antibody that blocks PD-L1 and PD-L2 binding to the PD-1 receptor with high potency at a unique site, enabling the immune system to activate and kill tumors. It is the only FDA-approved therapy for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, indicated for use in combination with chemotherapy or as monotherapy. It is sold to oncologists, hospitals, and cancer treatment centers in the United States.
  • Tagmokitug (anti-CCR8) Tagmokitug is a highly selective anti-CCR8 cytolytic antibody (ADCC-enhanced) designed to selectively deplete tumor resident regulatory T cells (Tregs) that suppress anti-tumor immune response, while sparing T cells and CCR8-negative Tregs in normal tissue. It is being developed for solid tumor indications including metastatic castration-resistant prostate cancer.
  • Casdozokitug (anti-IL-27) Casdozokitug is a first-in-class anti-IL-27 antibody antagonist designed to inhibit the immunosuppressive activity of IL-27 cytokine, enabling anti-tumor immune activation when combined with other cancer therapies including anti-PD-1 inhibitors. It has received FDA Orphan Drug designation for hepatocellular carcinoma.

Quantifiable outcome

  • 38% reduction in risk of death (HR 0.62) and 31-month improvement in median OS (64.8 vs 33.7 months) with LOQTORZI plus chemotherapy vs chemotherapy alone in nasopharyngeal carcinoma
  • +1 more outcomes

Companies that use Coherus Biosciences

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Coherus Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Coherus Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Zumutor BiologicscoreStrategic or Co-development Partner · 23 June 2026Clinical collaboration to evaluate ZM008 in combination with LOQTORZI (toripalimab-tpzi). Both parties will retain their respective commercial rights. No additional details regarding financial terms disclosed.
  • Johnson & JohnsoncoreStrategic or Co-development Partner · 4 February 2026Clinical supply agreement for a Phase 1b trial evaluating JNJ's pasritamig (T-cell engaging bispecific antibody) in combination with Coherus's tagmokitug in metastatic castration-resistant prostate cancer (mCRPC). Oppenheimer cited this as additional large pharma validation of the CCR8 target.
  • Apotex Inc.coreChannel Partner/ Reseller/ Distributor · 23 October 2025Licensing agreement granting Apotex exclusive rights to commercialize and sell LOQTORZI in Canada. Apotex received Health Canada approval for LOQTORZI as the first and only Health Canada-approved immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer. This marks Apotex's first novel biologic therapy.
  • Intas PharmaceuticalsminorOthers · 1 August 2025Intas Pharmaceuticals acquired the Udenyca franchise from Coherus BioSciences for $558.4 million, strengthening both companies' positions in the pegfilgrastim biosimilar segment. The deal closed in August 2025.
  • Inovio PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2024Partnership to advance DNA-based cancer immunotherapies combining INO-3113 with LOQTORZI for HPV-associated cancers.
  • Surface Oncology Inc.coreStrategic or Co-development Partner · 1 September 2023Coherus acquired Surface Oncology in a stock-for-stock transaction valued at up to $65 million, expected to close in Q3 2023. The acquisition expanded Coherus' immuno-oncology pipeline with SRF388 (now casdozokitug, anti-IL-27) and SRF114 (now tagmokitug, anti-CCR8), targeting the tumor microenvironment.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Coherus Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Owner of Keytruda (pembrolizumab), the dominant PD-1 inhibitor and Coherus's primary competitor in the broader checkpoint inhibitor space. While not a direct competitor in NPC, Keytruda represents the benchmark that any LOQTORZI label expansion will be measured against. Both companies operate in immuno-oncology with monoclonal antibody platforms.
  • Bristol-Myers Squibb: Owner of Opdivo (nivolumab), the second-leading PD-1 inhibitor globally. BMS has board representation connected to Coherus through former employees, and Opdivo competes with LOQTORZI in shared indications (head/neck cancer, gastric cancer). BMS represents the established PD-1 incumbent that Coherus must differentiate against.
  • Regeneron Pharmaceuticals: Established antibody platform company with multiple FDA-approved biologics including Libtayo (cemiplimab, a PD-1 inhibitor). Regeneron is a broad incumbent in monoclonal antibody therapeutics with a deep pipeline in immuno-oncology, oncology bispecifics, and inflammation — directly relevant to Coherus's IO antibody platform approach.
  • Gilead Sciences: Major biopharmaceutical company with oncology franchise including Trodelvy (ADC) and cell therapy via Kite. Gilead has a history of acquiring smaller oncology companies (Immunomedics, Forty Seven) and Coherus CFO Bryan McMichael previously worked at Gilead. While not a direct PD-1 competitor, Gilead is a relevant strategic acquirer and peer in the oncology therapeutics space.

Direct peers

  • BeiGene: Commercializes tislelizumab, a Chinese-developed PD-1 antibody with global commercialization. BeiGene is the most direct competitive peer to Coherus — a smaller biopharmaceutical company that has leveraged a Chinese-originated PD-1 antibody to build a US/EU oncology franchise, mirroring Coherus's toripalimab strategy. Both companies target similar hematology/oncology indications with checkpoint inhibitors.
  • Innovent Biologics: Chinese biopharmaceutical company that developed sintilimab (PD-1) and partners with Eli Lilly for international markets. Innovent is a direct strategic peer to Coherus in bringing a Chinese-originated PD-1 antibody to global markets, with overlapping oncology indications and similar partnership-driven commercial models.

Peers

  • Shanghai Junshi Biosciences: Original developer of toripalimab (LOQTORZI's active ingredient) and Coherus's licensor for US/Canada rights. Junshi is the originator peer — both companies commercialize the same molecule in different geographies, with Coherus holding North American rights. Junshi also commercializes other immuno-oncology assets including anti-PD-L1 (adebrelimab) and anti-BTLA (tifcemalimab), making it a directly comparable Chinese immuno-oncology peer.

Emerging players

  • MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies and antibody-drug conjugates for cancer, including PD-1 inhibitors and Fc-engineered antibodies. MacroGenics is a comparable emerging immuno-oncology peer with similar size and pipeline-stage assets targeting solid tumors with antibody-based mechanisms.
  • Werewolf Therapeutics: Clinical-stage immuno-oncology company developing INDUKINE therapeutics (tumor microenvironment-targeted immunotherapies). Werewolf focuses on overcoming immune resistance through innovative mechanisms — directly comparable to Coherus's CCR8/IL-27 tumor microenvironment approach.
  • Compugen: Israel-based clinical-stage immuno-oncology company developing computational-discovered antibody therapeutics targeting novel immune checkpoints, including PVRIG and TIGIT. Compugen's AI-driven antibody discovery and focus on next-generation immune checkpoints parallels Coherus's portfolio approach to overcoming immune resistance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Coherus Biosciences social profiles

Digital presence

Coherus Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coherus Biosciences leadership team

Management profile

Number of profiles

Profiles16 records

Coherus Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Coherus Biosciences funding detail

Funding detail

Funding overview

Funding rounds20 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coherus Biosciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coherus Biosciences

What does Coherus Biosciences do?

Coherus Biosciences (also known as Coherus Oncology) develops, manufactures, and commercializes biologic therapeutics for oncology. Its commercial product LOQTORZI (toripalimab-tpzi) is an FDA-approved next-generation anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma. The company is also advancing a clinical pipeline of novel immuno-oncology antibodies including tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27) that target the tumor microenvironment to overcome immune resistance in solid tumors.

Is Coherus Biosciences a public or private company?

Coherus Biosciences is a public company. It is classified as public and is currently operating.

When was Coherus Biosciences founded?

Coherus Biosciences was founded in 2010. It employs 101 to 250 people.

Where is Coherus Biosciences based?

Coherus Biosciences is headquartered in Redwood City, United States, in the North America region.

How does Coherus Biosciences make money?

Two revenue lines are on record. LOQTORZI Product Sales are the primary driver. The others are licensing and Royalty Revenue.

Who are Coherus Biosciences's main competitors?

Broad incumbents on record are Merck & Co., Bristol-Myers Squibb, Regeneron Pharmaceuticals and Gilead Sciences. Direct peers are BeiGene and Innovent Biologics. Shanghai Junshi Biosciences is listed as a peer. Emerging players are MacroGenics, Werewolf Therapeutics and Compugen.

Does Coherus Biosciences have an API?

No public API is recorded for Coherus Biosciences.

What industry is Coherus Biosciences in?

Coherus Biosciences's product category is Immuno-Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAMAK, Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeLobbying Update: $70,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed | CHRS Stock NewsCOHERUS BIOSCIENCES INC. disclosed $70,000 in lobbying spending for Q4 2026, covering oncology, drug production, and supply chain issues. The disclosure also includes CHRS stock activity, with 59 institutional investors adding shares and 99 reducing positions, and analyst buy ratings with a median price target of $7.5.Investing.comEarnings call transcript: Coherus BioSciences posts Q3 2026 revenue miss, shares riseCoherus BioSciences reported Q3 2026 revenue of $14.27 million, missing the $15.98 million forecast by 10.7%, while EPS of -$0.20 matched estimates. The company cut its LOQTORZI revenue guidance to $54-57 million and announced a 30% workforce reduction. It will focus tagmokitug development on esophageal cancer, with FDA discussions planned in early 2027.Investing.comCoherus Biosciences stock rating maintained at Outperform by OppenheimerOppenheimer reiterated an Outperform rating on Coherus Biosciences, keeping its $10 price target while the stock trades at $1.16. The firm cited early efficacy signals for tagmo in esophageal squamous cell carcinoma, supporting a path forward. Coherus plans regulatory discussions on these pathways with additional enrollment.American Banking and Market NewsContrasting Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)Coherus Oncology beats Molecular Partners on 9 of 12 factors, including higher revenue and earnings. Analysts give Coherus a stronger consensus rating with a 967.96% upside target versus Molecular Partners' 116.13% upside. Coherus also has lower volatility and higher institutional ownership.Markets DailyCritical Analysis: Coherus Oncology (NASDAQ:CHRS) and Emergent Biosolutions (NYSE:EBS)Coherus Oncology and Emergent Biosolutions are compared on profitability, analyst ratings, and institutional ownership. Coherus has a higher consensus rating and a larger potential upside, while Emergent trades at a lower price-to-earnings ratio. Coherus's consensus target price is $11.00 versus $10.00 for Emergent.Defense WorldComparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)Coherus Oncology and Molecular Partners are compared on revenue, valuation, and analyst ratings. Coherus has higher revenue and earnings, but Molecular Partners trades at a lower P/E ratio. Analysts favor Coherus with a higher consensus rating and greater upside.Markets DailyHead to Head Survey: Coherus Oncology (NASDAQ:CHRS) vs. Molecular Partners (NASDAQ:MOLN)Coherus Oncology and Molecular Partners are compared on profitability, ownership, analyst ratings, and valuation. Coherus has higher revenue and earnings, stronger institutional ownership, and a higher consensus price target, beating Molecular Partners on 9 of 13 factors.Markets DailyHead-To-Head Survey: Coherus Oncology (NASDAQ:CHRS) vs. Capricor Therapeutics (NASDAQ:CAPR)Coherus Oncology beats Capricor Therapeutics on 8 of 14 factors, including higher revenue and earnings. Analysts give Coherus a stronger consensus rating and a higher upside potential of 848.28% versus 238.37% for Capricor.American Banking and Market NewsFinancial Contrast: Coherus Oncology (NASDAQ:CHRS) vs. Capricor Therapeutics (NASDAQ:CAPR)Coherus Oncology beats Capricor Therapeutics on 8 of 14 factors, including higher revenue and earnings. Analysts rate Coherus more favorably with a higher consensus price target and greater upside potential.Seeking AlphaCoherus: 'Hold' On Several 2026 Catalysts And Casdozokitug HCC Drug DevelopmentCoherus Oncology, Inc. retains a "Hold" rating as it approaches multiple pivotal data readouts for its lead oncology candidates in the second half of 2026. The initial phase 2 CADILYZE data for casdozokitug in first-line unresectable HCC is anticipated in Q4 2026, which could be a major turning point for the company. However, Coherus faces near-term cash constraints with funding only sufficient for the next 12 months, raising potential dilution risks if further capital is needed.